ascentage.com (AAPGV): Operating Profitability

AAPGV (Ascentage Pharma Group Ltd) - company brandmark

Risks for Ascentage Pharma Group (AAPGV) depend on the efficacy of olverembatinib in leukemia therapy, which determines the operating margin on the GURU.Markets chart, where the current value is -220.00. Business development relies on large-scale R&D investments in apoptosis inhibitors. The brand's high authority among hematologists and global partnerships confirm the company's significant therapeutic potential in the fight against oncology.

AAPGV - ascentage.com Operating Profit Ratio over the range 01/25/2025 - 11/19/2026

Summary analytical data breakdowns for Ascentage Pharma Group (AAPGV)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental company analysis:Ascentage Pharma Group Ltd
Finished products of Ascentage

Operating margin determines the portion of revenue remaining after all production costs are paid, but before accounting for debt obligations and taxes, serving as an indicator of resource management efficiency. By analyzing the operating margin chart for Ascentage Pharma Group (AAPGV), an investor can assess the extent to which costs for developing anti-cancer and anti-aging drugs translate into actual profit, confirming the viability of the business model.

Competitor analysis for Ascentage Pharma Group

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|Operating Profit Rate ACTU|CTOR - Operating Profitability|Profitability of Operations tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operating Profitability|FATE: Operating Profit Ratio|WHWK (Aadi Bioscience, Inc.) - Operating Margin|TCRX (TScan Therapeutics) - Operating Profit Ratio|Operating Profitability Champions Oncology (CSBR)|Profitability of Operations XBiotech USA|Operating Profitability CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Operating Return on Sales|RADX - Operating Profitability|ARTV - Operating Margin|Adlai Nortye Ltd (ANL) - Operating Profitability|Veru Pharma - Operating Profit Rate|Operating Profitability Tempest Therapeutics Corp|Return on Sales by Operating Profit XLO (Xilio Therapeutics, Inc.)|Operating Margin RENB|MURA (Mural Oncology) - Operating Profit Rate|Operating Margin KAPA (Kairos Pharma Ltd)|OKUR: Return on Sales by Operating Profit|GDTC: Operating Sales Margin|CRIS - Operating Margin|APLM: Operating Margin|Operating Return on Sales tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Operating Margin|Operating Margin Genprex Inc.|Operating Margin CLDI|Operating Sales Margin Sunshine Biopharma, Inc. SBFM|Operating Margin XBIO (Xenetic Biosciences)|Operating Profit Rate SLRX|PPBT - Operating Profitability|AONC (aoncology.com) - Return on Sales by Operating Profit|BGNE: Operating Margin|Checkpoint Therapeutics Inc (CKPT) - Operating Margin|ELEV (Elevation Oncology Inc.) - Operating Margin|icadmed.com (ICAD) - Profitability of Operations|Operating Margin IKNA|NTBL (Notable Labs) - Operating Profit Rate|Operating Margin VIRX (Viracta Therapeutics)|Profitability of Operations MorphoSys AG (MOR)|NAYA Biosciences Corp - Operating Margin